Fasifree 10% w/v Oral Suspension

Country: Irlanda

Lingwa: Ingliż

Sors: HPRA (Health Products Regulatory Authority)

Ingredjent attiv:

Triclabendazole

Disponibbli minn:

Cross Vetpharm Group Limited

Kodiċi ATC:

QP52AC01

INN (Isem Internazzjonali):

Triclabendazole

Dożaġġ:

10 percent weight/volume

Għamla farmaċewtika:

Oral suspension

Tip ta 'preskrizzjoni:

LM: Licensed Merchant as defined in relevant national legislation

Grupp terapewtiku:

Cattle, Sheep

Żona terapewtika:

triclabendazole

Indikazzjonijiet terapewtiċi:

Endoparasiticide

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2002-02-22

Karatteristiċi tal-prodott

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Fasifree 10% w/v Oral Suspension.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oral suspension.
A white to off-white oral suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle and Sheep.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment and control of adult, immature and early immature
stages of liver fluke (_Fasciola hepatica)_ susceptible to
triclabendazole.
4.3 CONTRAINDICATIONS
Do not use in animals known to be hypersensitive to the active
substance.
Each ml contains:
ACTIVE SUBSTANCE
Triclabendazole
100 mg
EXCIPIENTS
Methyl Parahydroxybenzoate (E218) Ph.Eur.
2.0 mg (preservative)
Propyl Parahydroxybenzoate (E216) Ph.Eur.
0.2 mg (preservative)
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_1_
_/_
_0_
_8_
_/_
_2_
_0_
_1_
_5_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_1_
_5_
_9_
_8_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk of development of resistance and could
ultimately result in ineffective therapy:
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
Underdosing, which may be due to underestimation of body weight,
misadministration of the product, or lack of
calibration of the dosing device.
Suspected clinical cases of re